PCSK9 Inhibitor After Heart Transplant Turns in Mixed Results

(MedPage Today) — NEW ORLEANS — Treatment with the PCSK9 inhibitor alirocumab (Praluent) safely lowered LDL cholesterol versus placebo in transplant patients already on rosuvastatin, but did not reduce the development of cardiac allograft vasculopathy…